🇺🇸 FDA
Patent

US 7541035

Immunogenic peptides for the treatment of prostate and breast cancer

granted A61KA61K2039/53A61K2039/57

Quick answer

US patent 7541035 (Immunogenic peptides for the treatment of prostate and breast cancer) held by The United States of America as Represented by the Secretary of the Department of Health and Human Services expires Mon May 28 2029 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America as Represented by the Secretary of the Department of Health and Human Services
Grant date
Tue Jun 02 2009 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 28 2029 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
25
CPC classes
A61K, A61K2039/53, A61K2039/57, A61K2239/49, A61K2239/58